Lab-Grown lung tumors could reveal why some drugs work and others fail

NCT ID NCT07697716

Not yet recruiting Knowledge-focused Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study takes leftover tumor samples from people with EGFR-mutant non-small cell lung cancer and grows them in the lab as cell cultures and organoids. Researchers will test different anti-EGFR drugs on these models to see which ones work best for each type of mutation and explore how resistance develops. The goal is to make lung cancer treatment more personalized and effective without interfering with patients' regular care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors choose the most effective anti-EGFR therapy for each patient's specific mutation, reducing trial-and-error and improving outcomes.
What could go wrong: This is a small, observational lab study using cell models, not a treatment trial. Findings may not translate directly to real patient responses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG EGFR GENE MUTATION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.